Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis

Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis

Transforming growth factor β receptor (TGF-β1R) and receptor tyrosine kinases (RTKs), such as VEGFRs, PDGFRs and FGFRs are considered important therapeutic targets in blocking myofibroblast migration and activation of idiopathic pulmonary fibrosis (IPF). To screen and design innovative prodrug to si...

Full description

Bibliographic Details
Main Authors:	Rui Wang, Jian Xu, Rong Yan, Huanbin Liu, Jingxin Zhao, Yuan Xie, Wenbin Deng, Weiping Liao, Yichu Nie
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Pharmacology
Subjects:	idiopathic pulmonary fibrosis virtual screening machine learning multitarget inhibitors activity evaluation
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.998245/full

Similar Items

Idiopathic pulmonary fibrosis: current diagnosis and treatment
by: Alexandre Franco Amaral, et al.
Published: (2023-08-01)

A qualitative exploration of people living with idiopathic pulmonary fibrosis experience of a virtual pulmonary rehabilitation programme
by: Orlagh O’Shea, et al.
Published: (2022-11-01)

Idiopathic Pulmonary Fibrosis and Telomeres
by: Alba Mulet, et al.
Published: (2022-11-01)

Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair?
by: Swiss Medical Weekly
Published: (2003-07-01)

Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
by: Wei Yan, et al.
Published: (2015-01-01)

The Role of Microbiome and Virome in Idiopathic Pulmonary Fibrosis
by: Paschalis Ntolios, et al.
Published: (2021-04-01)

Multitarget-Based Virtual Screening for Identification of Herbal Substances toward Potential Osteoclastic Targets
by: Siripat Chaichit, et al.
Published: (2022-03-01)

Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis
by: Roxana-Elena Cîrjaliu, et al.
Published: (2023-06-01)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
by: Hehua Guo, et al.
Published: (2023-08-01)

Clinical course and management of idiopathic pulmonary fibrosis
by: Caitlin Quinn, et al.
Published: (2019-12-01)

Pulmonary vascular dysfunction without pulmonary hypertension: A distinct phenotype in idiopathic pulmonary fibrosis
by: Steven D. Nathan, et al.
Published: (2024-01-01)

Association between timing of intubation and mortality in patients with idiopathic pulmonary fibrosis
by: Eunhye Bae, et al.
Published: (2022-11-01)

Diagnostic Approaches for Idiopathic Pulmonary Fibrosis
by: Jae Ha Lee, et al.
Published: (2024-01-01)

Herbal Remedies Effective on Treating Idiopathic Pulmonary Fibrosis
by: Aditi Chaudhary, et al.
Published: (2023-12-01)

Evaluation of repolarization dispersion in patients with idiopathic pulmonary fibrosis
by: Ferhat Eyyupkoca, et al.
Published: (2022-06-01)

Epidemiologic Analysis of Taiwanese Patients with Idiopathic Pulmonary Fibrosis
by: Sheau-Ning Yang, et al.
Published: (2020-12-01)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
by: Yuji Iwanami, et al.
Published: (2022-09-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
by: Spagnolo Paolo, et al.
Published: (2012-11-01)

Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?
by: Ioannis Tomos, et al.
Published: (2023-10-01)

Characteristics of gastro-esophageal reflux in patients with idiopathic pulmonary fibrosis
by: Sameh Embarak, et al.
Published: (2015-04-01)

IDIOPATHIC PULMONARY FIBROSIS. CORRECTION OF ERRORS
by: A. L. Yudin, et al.
Published: (2018-12-01)

The Impact of Chronic Comorbidities on Outcomes in Acute Exacerbations of Idiopathic Pulmonary Fibrosis
by: Saqib H. Baig, et al.
Published: (2024-01-01)

Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions
by: Anna Stainer, et al.
Published: (2021-06-01)

Pregnancy in a Patient with Idiopathic Pulmonary Fibrosis: A Case Report
by: Rebecca Horgan, et al.
Published: (2023-01-01)

The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis
by: Yahan Xu, et al.
Published: (2023-11-01)

Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics
by: Yu Fujita
Published: (2022-08-01)

Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension
by: Dalia D. Hadi, et al.
Published: (2023-11-01)

Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks
by: Filippo Patrucco, et al.
Published: (2023-03-01)

The Genetic and Epigenetic Footprint in Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis: A State-of-the-Art Review
by: Claudio Tirelli, et al.
Published: (2022-12-01)

Circular RNAs and their roles in idiopathic pulmonary fibrosis
by: Akshaya Surendran, et al.
Published: (2024-02-01)

Biomarkers of cellular senescence in idiopathic pulmonary fibrosis
by: Zaira Aversa, et al.
Published: (2023-04-01)

Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis
by: Keisuke Anan, et al.
Published: (2022-10-01)

Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
by: I-Chen Chen, et al.
Published: (2022-05-01)

PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis
by: Sissel Kronborg-White, et al.
Published: (2021-11-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01)

Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment
by: Michelle B. Herberts, et al.
Published: (2023-08-01)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
by: Quentin Philippot, et al.
Published: (2023-03-01)

Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels
by: Yasuhiko Koga, et al.
Published: (2019-05-01)

Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis
by: Weiwei Zhu, et al.
Published: (2024-01-01)